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Summary 
The extent of uptake of gamma interferon (7-IFN) in various strata of 
hairless mouse, human and hamster skin upon application of a liposomal 
formulation and an aqueous solution were determined by in vitro diffusion cell 
experiments. For each of the animal species studied, 70-80% of the liposomally 
entrapped IFN was deposited onto or penetrated into the skin as determined 24 
h after in vitro application. However, a significant fraction of this total amount 
(~  0.25-0.30) is either adsorbed to or associated with the stratum corneum. The 
drug content found in the deeper skin strata, where the receptor sites reside, 
suggests that drug deposition is strongly influenced by the skin species tested. 
The percent of applied drug found in this strata 24 h after application followed 
the order: hamster (6.1) >> human (0.9) > hairless mouse (0.3), although the 
amounts of drug in the total skin of each species tested were approximately the 
same. This indicates that the deposition of drug into the living epidermis and/or 
dermis cannot be predicted by determination of the amount of drug in the total 
skin. The amounts in the deeper skin strata were also in the order of increasing 
number of follicles/hair in the skin species, suggesting that the transfollicular 
route is an important pathway for liposomal topical therapeutics. 
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Gamma-interferon (7-IFN), a major endogenously produced activation 
factor (MAF), is a glycoprotein secreted predominantly by sensitized T-cells in 
response to antigen (Murray, 1988). The recent availability of large quantities 
of purified 7-IFN through recombinant DNA technology (Murray et al., 1987) 
has generated interest in its use as a therapeutic agent for infections (Murray, 
1988; Nathan et al., 1986). In the case of skin diseases, the therapeutic potential 
of y-IFN may be limited by rapid clearance from the circulation and an 
inability to selectively deliver the molecule to the appropriate cells. When 
administered systemically, 7-IFN could result in undesirable side-effects and 
still be inadequate to suppress skin symptomology. 
Liposomes have shown great potential as a drug delivery system. An 
assortment of molecules, including peptides and proteins, have been 
incorporated in liposomes, which can then be administered by different routes 
(Siciliano, 1985; Westerhof, 1985; Komatsu et al., 1986). Due to their high 
degree of biocompatibility, liposomes were initially used as delivery systems for 
intravenous delivery. It has since become apparent that liposomes can also be 
useful for delivery of drugs by other routes of administration, especially by 
topical application (Egbaria and Weiner, 1990). 
Weiner et al. reported that topical application of liposomally entrapped 
alpha-interferon (e-IFN) prepared using the dehydration/rehydration method 
(DRV) caused a reduction of lesion scores in the cutaneous herpes simplex 
virus type 1 guinea pig model (Weiner et al., 1989). Egbaria et al. (1990) using 
in vitro studies also reported that liposomal e-IFN prepared by the DRV 
method was more effective in facilitating e-IFN penetration into the deeper 
skin strata where the basal cell layers reside. In this study, we compare the 
deposition of an aqueous solution and a liposomal dispersion of 7-IFN 
prepared using the DRV method, into various strata of mouse, hamster and 
human skin using in vitro diffusion cell studies. 
Materials and Methods 
Materials 
Cholesterol (CH) and (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic 
acid]) (HEPES) free acid were obtained from Sigma (St. Louis, MO). Egg 
lecithin (PC) and phosphatidylserine (PS) were obtained from Avanti Polar 
Lipids (Birmingham, AL). ~-Tocopherol (a-T) was obtained f rom Eastman 
Kodak Co. (Rochester, NY). Lyophillized recombinant 7-IFN in vials was 
supplied by Genentech, Inc. (South San Francisco, CA). 125I-labeled lyophilized 
recombinant ~-IFN was obtained from New England Nuclear corporation 
(Boston, MS). All solvents used were of chromatographic (high-performance 
liquid chromatography) grade, and the water used was double-distilled, 
deionized, and filtered with a Milli-Q system (Millipore Corp., Bedford, MS). 
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Formulations 
Dehydration/rehydration liposomes (DRV) containing PC/CH/PS at a 
molar ratio of 1:0.5:0.1 were prepared by a modification of the method 
reported by Kirby and Gregoriadis (Kirby and Gregoriadis, 1984). Briefly, 
appropriate amounts of the various lipids, contained in a flask, were dissolved 
in chloroform/methanol (2:1; v/v). The total lipid concentration was 50 mg/ml 
and one percent ~-T (an antioxidant) was added to the lipid phase of the 
liposomes. The solvents were removed using a rotoevaporator under vacuum at 
45°C. The resultant film was dried overnight in a desiccator to remove any 
residual solvent. An appropriate aliquot of aqueous 7-IFN stock solution in 
0.05 M HEPES buffer (pH 7.4) containing 0.1% human serum albumin and 
trace amounts of radiolabeled 7-IFN was then added and the mixture was 
hydrated at 30°C for about an hour. Intermittent vortexing was required for 
complete hydration. The resultant dispersion was then dehydrated at 45°C 
under vacuum using the rotoevaporator. When the liposomal suspension 
became very viscous, an amount of water, equivalent to that removed was 
reintroduced into the viscous suspension. The rehydrated liposomes were 
allowed to equilibrate for about 45 min at 30°C. The dispersion containing 100 
#g/ml 7-IFN was then stored at 4°C overnight before use in the diffusion 
experiments. 
An aqueous solution was prepared by dissolving ~-IFN in an appropriate 
volume of 0.05 M HEPES isotonic buffer (pH 7.4) containing 0.1% human 
serum albumin to obtain a solution containing 100/~g/ml 7-IFN. 
Diffusion experiments 
Full thickness human abdominal skin was obtained at autopsy a few hours 
post-mortem. Full thickness hairless mouse and hamster skin was excised from 
freshly sacrificed animals and immediately used after removing subcutaneous 
fat. The skin was mounted on a Franz diffusion cell with a nominal surface area 
of 2 cm 2 and a receiver compartment with a 7-ml capacity (Crown Glass, 
Somerville, N J). The epidermal side of the skin was exposed to ambient 
conditions while the dermal side was bathed by a 0.05 M isotonic HEPES 
buffer (pH 7.4) containing 0.1% human serum albumin. The receiver solution 
was stirred continuously using a small Teflon-covered magnet. Care was 
exercised to remove any air bubbles between the underside of the skin and 
solution in the receiver compartment. The temperature of the receiver was 
maintained at 37°C. Following mounting of the section of skin, 200 #1 of the 
test formulation was applied to the epidermal surface. A minimum of 3 cells 
were used for each formulation with each skin species. All experiments were 
carried out with non-occluded donor compartments. After 24 h, the 
experiments were stopped and the diffusion set-up was dismantled for assay 
of radiolabeled lipids. 
Assay of radiolabeled markers 
Upon dismantling, the donor compartment of the cell was rinsed carefully 5 
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times with 0.5 ml HEPES buffer containing 0.1% human serum albumin. The 
skin was then removed and it too was rinsed twice with 3 ml of the same buffer. 
The washing procedure was found to be sufficient to remove > 99% of the 
formulation when determined at time zero. All washings were collected and 
assayed for radiolabel. Following the rinsing procedure, the skin patch was 
mounted on a board and a piece of adhesive tape (Scotch Magic Tape, 810, 3M 
Commercial Office Supply Division, St. Paul, MN), 1.9 cm wide and about 6 
cm long, was used to strip the skin. The tape was of sufficient size to cover the 
area of skin that was in contact with the formulation. The stripping technique 
used was similar to that used in our earlier studies (Egbaria and Weiner, 1990). 
Twenty-five, ten and fifteen strippings were carried out for human, hairless 
mouse and hamster skin, respectively, and each strip was analyzed separately 
for radiolabeled drug. The donor, skin rinses, receiver solutions, the tape 
strippings and remaining skin were assayed for radiolabeled drug using a 5000 
series Gamma Minaxi 7-counter (Packard Instrument Co. Inc., Downers 
Grove, IL). 
A 10% solution of trichloroacetic acid in HEPES buffer (pH 7.4) was added 
to the samples and the contents were thoroughly mixed on a Vortex mixer (The 
Vortex Manufacturing Co., Cleveland, OH) and further incubated for 48 h to 
allow intimate contact between the protein precipitant and the 7-IFN residing 
in the skin tissue. The mixture was centrifuged and the supernatant 
(representing the amount of free iodine label) was assayed. 
Results 
Table 1 show the 24 h in vitro uptake of 7-IFN from the aqueous solution 
and the liposomal formulation in the various strata of human, hairless mouse, 
TABLE 1 
Distribution of 7-interferon (expressed as percent formulation applied +_ S.D.; n = 3  5) in the 
various strata of the skin 24 h after in vitro topical application of dehydration/rehydration 
liposomes to full-thickness human, hairless mouse and hamster skin a 
Compartments Human Skin Hairless Mouse Hamster Skin b 
Liposomes Aq. Sol, Liposomes Aq. Sol. Liposomes Aq. Sol. 
Total Donor 22.6+0.8 90.7+3.9 20.9+0.8 91,4+_1.8 29.2+0.9 77.8_+1.5 
Surface Stratum 57.4_+3.0 5.7+2,1 32.5_+5.7 6,5_+3.1 30.2+3.2 11.8_+0.7 
Corneum 
Deeper Stratum 19.1+3.3 3.4+_2,1 46.3_+1.8 0.5_+0.06 34.9_+1.4 9.5+_1.5 
Corneum 
Deeper Skin Strata 0.9+0.9 0.2_+0.05 0.3+0.02 0.9-1-0.4 6.1±2.6 ~ 0.9+_0.3 
Total Skin 77.4_+0.3 9.3___4.2 79.1 _+3.9 7.8_+2.8 70.8+0.9 22.2_+2.5 
Receiver 0.01 _+_0.0 0.03_+0.0 0.08+__0.1 0.8_+1.4 0.00_+0.0 0.02_+0.0 
a All values were corrected to 100% of recovered radioactivity. 
b Values represent dorsal skin sections only. 
c For abdominal skin, the value= 2.9 +_0.23). 
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hamster skin, respectively. The amount of 7-IFN adhering to the stratum 
corneum surface was determined by analysis of the first two tape strippings. 
The amount of 7-IFN penetrating the deeper stratum corneum was determined 
by analysis of the remaining strips (3-25 for human skin, 3-10 for hairless 
mouse skin, 3-15 for hamster skin). The amount of 7-IFN penetrating the 
deeper skin strata was determined by analysis of the remainder of the full- 
thickness skin. 
Discussion 
The efficacy of liposomal 7-IFN, prepared using the dehydration/rehydra- 
tion method, compared to an aqueous ),-IFN formulation, in facilitating drug 
deposition was tested using hairless mouse, human and hamster skin. 
Liposomal ~-IFN prepared by the DRV method was shown to be more 
effective in reducing herpes lesions in a guinea pig model (Weiner et al., 1989). 
The results of the 24 h in vitro studies with phospholipid DRV and aqueous 7- 
IFN using the three skin species shown in Table 1. It is evident from Table 1 
that liposomal 7-IFN formulations are superior to aqueous formulation in 
facilitating drug deposition into hairless mouse, human and hamster skin. For 
the three skin specimens tested, the total amount of 7-IFN in the skin was 
about 70-80% compared to only 10-20% with an aqueous solution. 
An examination of Table 1 also reveals that a significant fraction of the drug 
in the skin after liposomal treatment is either adsorbed to or associated with the 
stratum corneum. The amounts of ~-IFN deposited in the deeper skin strata 
after removal of the stratum corneum, appear to be strongly dependent on the 
nature of the skin specimen used. This is particularly evident for the drug 
deposition in the deeper skin strata after liposomal treatment. The amount of 7- 
IFN in the deeper skin strata 24 h after in vitro liposomal treatment followed 
the order: hairless mouse < human << hamster skin. It is therefore clear that 
although the total amounts of 7-IFN in the three skin species were similar, the 
amount of drug found in the deeper skin strata (where the receptor sites reside) 
show dramatic differences. Thus, it is apparent from these studies that it is not 
possible to predict drug deposition in the deeper skin strata by determining the 
total amounts of drug associated with the skin. The dramatic dependence of 
drug deposition amounts in the deeper skin strata on the skin specimen further 
suggests that liposomal drug transport into strata below and beyond the 
stratum corneum may occur via a follicular route. To a first approximation, it 
is reasonable to assume that the number of follicles in a given skin specimen 
would be proportional to the number of hairs in that specimen. Although the 
absence of hair does not denote absence of follicles (such as the forehead), the 
presence of hair is a positive indication of the presence of follicles. Thus, hair 
density should be proportional to the number of hair follicles. Based on this 
proportionality, the follicular pathway would be in the order: hamster >> 
human > hairless mouse. Further, it is well known that the follicles in mice, 
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rendered hairless genetically, are not fully developed ancl may be in a state of 
atrophy. It is also clear that the number of follicles in human abdominal skin is 
quite low compared to that in the forehead, back, postauricular area or the 
forearms (Szabo, 1958). An examination of the amounts of 7-IFN deposited 
from liposomal formulations in the deeper skin strata of hamster skin reveals 
some interesting trends. It is found that the amounts are higher when dorsal 
skin is used compared to abdominal skin. These differences may be related to 
the number and density of follicles in the skin specimen. It is also clear that 
even for abdominal skin, wherein the follicular density is lower, liposomal 
formulations allow substantially greater deposition of 7-IFN in the deeper skin 
strata compared to that from aqueous solutions. Considering all the above 
factors, we believe that the number of follicles in the skin species tested is in the 
order: hamster >> human > hairless mouse skin. Differences in percutaneous 
absorption of a variety of drugs in various animal species have been discussed 
in terms of differences in follicular densities (Barry, 1983). 
We have also recently demonstrated that the follicular route is an important 
pathway in the transport of drugs from liposomal formulations (Weiner et al., 
1991). Although the relative importance of the lipoidal or stratum corneum- 
mediated pathway and the follicular pathway in facilitation-enhanced 
permeation of drugs such as °/-IFN is still unclear, it is probable that the 
latter pathway might be predominantly responsible, especially because a 
molecule such as 7-IFN is not expected to readily permeate the stratum 
corneum due to its size (molecular weight) and hydrophilicity. The 
proportionality of 7-IFN amounts in the deeper skin strata of various skin 
species with the estimated follicular density therefore appears to corroborate 
such a pathway for 7-IFN transport from liposomal formulations. 
It is recognized that differences in stratum corneum lipid compositions and 
thicknesses may play some role in determining such differences. However, the 
major differences in drug deposition in the deeper skin strata appears to be 
closely related to the size and density of follicles in the skin sample. 
The importance of the lipoidal pathway should not be minimized, however. 
When an applied liposomal drug suspension begins to dry, dehydration 
transforms the liposomes into lipid bilayer structures that adhere or bind 
strongly to the surface of the skin. Such binding may occur between liposomal 
lipid bilayers and corneocytes or between liposomal and stratum corneum 
bilayers. The adhesive strength appears to be quite high judging from the 
inability of simple rinsing procedures to dislodge a significant portion of the 
applied liposomal lipids. The 'surface' liposomal bilayers containing drug 
provide a drug reservoir allowing sustained release of the drug, specifically 
small lipophilic drugs such as hydrocortisone, across the stratum corneum into 
the dermis and blood vasculature (Jacobs et al., 1988; Gesztes and Mezei, 
1988). The liposomal lipid bilayers formed on the surface after dehydration 
present an additional and substantial barrier of drug diffusion. It is possible, 
therefore, to control drug release into and across skin by controlling the 
amounts of liposomal lipids applied. 
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